Medicure Biotech Rakete ! - 500 Beiträge pro Seite

[Flanelli]

Medicure Inc.

TSX VENTURE : MPH
OTCQB : MCUJF

WKN: A1J7TZ
ISIN: CA58469E4085

Our Products

AGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXAL™ - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need

http://www.medicure.com

http://www.medicure.com/about.html

Nachdem die kanadische Biotechgesellschaft am 11. Oktober die FDA Zulassung für Aggrastat HDB vermelden konnte habe der Titel über 150% auf 0,53 Kanadische Dollar hochschnellen können.

Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT(R)



http://www.marketwired.com/press-release/medicure-announces-…

Schon vor den sehr guten Nachrichten hätten die Analystenkursziele zwischen 2,06 und 3,25 Kanadischen Dollar gelegen und könnten möglicherweise in den nächsten Wochen sogar noch angehoben werden.
Bei nur 12,2 Millionen ausstehenden Aktien beträgt die derzeitige Marktkapitalisierung lediglich 3,66 Millionen kanadische Dollar. (Kurs aktuell 0,30 CAD $)
Aufgrund der bedeutenden Produktpalette und dem damit verbundenen enormen Marktanteil verspricht die Aktie erhebliches Kurspotential. Eine kurzfristige Verdreifachung des Kurses scheint in Anbetracht des geringen Börsenwert realistisch.


"We are pleased with the FDA approval of the AGGRASTAT HDB regimen," stated Dr. Albert D. Friesen, CEO of Medicure Inc. "The inclusion of the contemporary, guideline-recommended dosing regimen for AGGRASTAT is expected to have a positive impact on sales over the coming months."AGGRASTAT currently has a 2% share of the approximately $300 million US glycoprotein (GP) IIb/IIIa inhibitor market, but continues to be the leading GP IIb/IIIa inhibitor outside of the US where the Aggrastat HDB regimen has already been approved. The Company is currently enrolling patients in the SAVI-PCI study, which compares the Aggrastat HDB regimen against Integrilin® (eptifibatide) (Merck & Co., Inc.), which has annual US sales of greater than $230 million.

[Flanelli]

Antwort auf Beitrag Nr.: 45.700.335 von Flanelli am 26.10.13 11:40:10

Tardoxal™ is a naturally occurring, small molecule drug that is in development for a neurological condition known as Tardive Dyskinesia (TD). Tardoxal has demonstrated activity on a number of biological factors believed to be responsible for TD. Medicure has conducted extensive research and development activity with the molecule and established its safety profile in clinical trials enrolling over 4,000 patients. The product is currently being evaluated in a Phase II proof-of-principle clinical study.About Tardive DyskinesiaTardive dyskinesia (TD) is a socially stigmatizing and potentially irreversible long-term disorder caused by treatment with antipsychotic medications which are generally prescribed for conditions such as schizophrenia and schizoaffective disorder. As a neurological disorder, TD has been linked with poor quality of life and increased medical morbidity and mortality. The condition is characterized by repetitive, involuntary, purposeless movements and may include grimacing, tongue protrusion, lip smacking, puckering and pursing of lips, and rapid eye blinking. TD can also lead to unintelligible speech, respiratory distress, postural imbalance, and depression. Management of TD is challenging for the clinician as dose reduction of the prescribed antipsychotic medication may be accompanied by worsening of symptoms or psychotic relapse. Despite extensive research, there are currently no FDA-approved drugs for the management or treatment of Tardive Dyskinesia.

[Gesprengt]

Correvio and AGGRASTAT ... Medicure and AGGRASTAT

http://www.medicure.com/tirofiban.html
http://www.medicure.com/aggrastat/

Cardiome is nearing a bid to buy Medicure

Canadische Brancheninsider erwarten kurzfristig eine weitere Übernahme von Cardiome. Das canadische Biotechnologie Unternehmen Medicure Inc. (V.MPH) wird aufgrund der AGGRASTAT US exklusiv Rechte als unmittelbarer Übernahmekandidat gehandelt. Die Übernahme von Correvio durch Cardiome ist ein cleverer Deal - die Übernahme von Medicure wäre ein Meilenstein.

 http://www.correvio.com/aggrastat_1http://...evio_llc?date=2…

Medicure's core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT. The Company has an experienced commercial team dedicated exclusively to the marketing of AGGRASTAT.The US rights to Aggrastat are owned by Medicure's subsidiary, Medicure International, Inc. (Barbados) and the product is distributed in the United States by Medicure's US subsidiary, Medicure Pharma, IncCorrevio does not have commercialisation rights for Aggrastat® in the USA.

[Gesprengt]

http://www.correvio.com/cardiome_to_acquire_correvio_llc?dat…